BR0009551A - Suspensão farmacêutica para beber - Google Patents

Suspensão farmacêutica para beber

Info

Publication number
BR0009551A
BR0009551A BR0009551-6A BR0009551A BR0009551A BR 0009551 A BR0009551 A BR 0009551A BR 0009551 A BR0009551 A BR 0009551A BR 0009551 A BR0009551 A BR 0009551A
Authority
BR
Brazil
Prior art keywords
drinking
pharmaceutical suspension
suspension
pharmaceutical
weight
Prior art date
Application number
BR0009551-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Christophe Lebon
Emmanuel Guerin
Pascal Suplie
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of BR0009551A publication Critical patent/BR0009551A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0009551-6A 1999-04-06 2000-04-06 Suspensão farmacêutica para beber BR0009551A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904251A FR2791888B1 (fr) 1999-04-06 1999-04-06 Suspension pharmaceutique buvable
PCT/FR2000/000870 WO2000059468A1 (fr) 1999-04-06 2000-04-06 Suspension pharmaceutique buvable

Publications (1)

Publication Number Publication Date
BR0009551A true BR0009551A (pt) 2002-05-28

Family

ID=9544041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009551-6A BR0009551A (pt) 1999-04-06 2000-04-06 Suspensão farmacêutica para beber

Country Status (9)

Country Link
EP (1) EP1165043A1 (fr)
CN (1) CN1351488A (fr)
AU (1) AU778364B2 (fr)
BR (1) BR0009551A (fr)
FR (1) FR2791888B1 (fr)
HU (1) HUP0200711A3 (fr)
IL (1) IL145768A0 (fr)
WO (1) WO2000059468A1 (fr)
ZA (2) ZA200108116B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411899B1 (fr) * 2001-08-01 2009-03-11 Novartis AG Composition de masquage de gout
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
JP6487534B2 (ja) 2014-09-05 2019-03-20 シンビオミックス セラピューティクス、エルエルシー 細菌性膣炎の治療に使用するためのセクニダゾール

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210785A (en) * 1984-01-13 1987-11-27 Battelle Development Corp Liquid dispersions of layered controlled release dosage forms
DE3900811A1 (de) * 1989-01-13 1990-07-19 Kali Chemie Pharma Gmbh Neue arzneiform
IE902829A1 (en) * 1989-08-14 1991-02-27 Eurand America Microencapsulated taste-masked water-insoluble nsaid drug¹materials
IL104093A (en) * 1991-12-31 1999-06-20 Abbott Lab Prolamine is expected to mask the taste of drugs given orally
EP0717992A3 (fr) * 1994-12-21 1998-03-25 McNEIL-PPC, INC. Formulations de suspension aqueuses pour applications pharmaceutiques
CA2219758A1 (fr) * 1995-05-09 1996-11-14 Jamesina Anne Fitzgerald Compositions comprenant du bismuth et un ou plusieurs antimicrobiens, pour la prevention et le traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
AU778364B2 (en) 2004-12-02
IL145768A0 (en) 2002-07-25
ZA200108206B (en) 2002-12-24
ZA200108116B (en) 2002-09-25
FR2791888B1 (fr) 2004-10-08
HUP0200711A2 (hu) 2002-07-29
WO2000059468A1 (fr) 2000-10-12
FR2791888A1 (fr) 2000-10-13
EP1165043A1 (fr) 2002-01-02
HUP0200711A3 (en) 2003-04-28
AU3825200A (en) 2000-10-23
CN1351488A (zh) 2002-05-29

Similar Documents

Publication Publication Date Title
TR200003735T2 (tr) Osteoporoz ve menopoz sendromuna bağlı rahatsızlıkların önlenmesi ve tedavileri
BR0013777A (pt) Compostos, formulações, bebidas, gêneros alimentìcios e usos terapêuticos que envolvem ou servem para preparar compostos de isoflavonas e seus análogos
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
HRP20040308A2 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
BR0007556A (pt) Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
BRPI0510848A (pt) derivados de pirrolotriazina úteis para o tratamento de distúrbios e doenças hiperproliferativos associados com a angiogênese
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BR0203172A (pt) Agentes terapêuticos para acondroplasia
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
BRPI9809468B8 (pt) Formulações farmacêuticas contendo voriconazol
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
WO2000015205A3 (fr) Utilisation d'inhibiteurs acetylcholinesterases pour la preparation de compositions pharmaceutiques destinees au traitement de syndromes de douleur fonctionnelle et/ou organique
PT1328268E (pt) Combinacao de catequina e quercetina para utilizacao farmaceutica ou dietetica
BR0009594A (pt) Composto derivado de amina ou um seu sal farmacologicamente aceitável, fármaco, agente de melhoria da tolerância a insulina, agente de abaixamento do açúcar no sangue, agente imunorregulador, agente inibidor de aldose-redutase, agente inibidor de 5-lipoxigenase, agente inibidor da formação de peróxido lipìdico, agente de ativação de ppar, agente de antiosteoporose, agente antagonista de leucotrieno, agente promotor de célula gordurosa, agente inibidor da proliferação de célula cancerosa ou agente antagonista de cálcio, composição farmacêutica e uso de um composto
FR2857596B1 (fr) Utilisation d'une composition cosmetique ou pharmaceutique comprenant un extrait riche en lupeol, a titre de principe actif, pour stimuler la synthese des proteines de stress
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
NO20000310D0 (no) Farmasoeytiske sammensetninger som inneholder vitamin D og kalsium, deres fremstilling og terapeutisk anvendelse
BR0015540A (pt) Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
EP1032556A4 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation
EP1736470A3 (fr) Dérivés de pyrimidine comme modulateurs du récepteur cannabinoide CB2
BR0009551A (pt) Suspensão farmacêutica para beber
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
WO2000054780A3 (fr) Formulation corticosteroidienne
BR0015172A (pt) Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.